Cytosorbents (NASDAQ:CTSO)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued on Tuesday, January 9th. They currently have a $14.00 price objective on the medical research company’s stock. HC Wainwright’s price objective suggests a potential upside of 84.21% from the company’s current price.
Other equities research analysts have also issued research reports about the company. ValuEngine raised Cytosorbents from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. Maxim Group set a $12.00 target price on Cytosorbents and gave the stock a “buy” rating in a research report on Monday, January 8th. Finally, B. Riley set a $11.00 target price on Cytosorbents and gave the stock a “buy” rating in a research report on Friday, December 22nd. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Cytosorbents has a consensus rating of “Buy” and an average price target of $10.65.
Cytosorbents (CTSO) opened at $7.60 on Tuesday. The company has a current ratio of 3.36, a quick ratio of 3.17 and a debt-to-equity ratio of 0.73. The stock has a market capitalization of $218.05, a PE ratio of -20.00 and a beta of -0.54. Cytosorbents has a 12 month low of $3.30 and a 12 month high of $7.90.
Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings results on Thursday, November 9th. The medical research company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.07). Cytosorbents had a negative return on equity of 233.72% and a negative net margin of 67.83%. analysts forecast that Cytosorbents will post -0.26 earnings per share for the current year.
In related news, CFO Kathleen P. Bloch sold 12,400 shares of the firm’s stock in a transaction that occurred on Friday, January 12th. The stock was sold at an average price of $7.75, for a total transaction of $96,100.00. Following the transaction, the chief financial officer now owns 241,038 shares in the company, valued at approximately $1,868,044.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Kathleen P. Bloch sold 32,400 shares of the firm’s stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $7.30, for a total value of $236,520.00. Following the transaction, the chief financial officer now owns 248,638 shares in the company, valued at approximately $1,815,057.40. The disclosure for this sale can be found here. Insiders have sold a total of 48,800 shares of company stock worth $360,620 in the last 90 days. 5.60% of the stock is currently owned by company insiders.
Several hedge funds have recently made changes to their positions in CTSO. Skylands Capital LLC grew its stake in shares of Cytosorbents by 45.1% in the 4th quarter. Skylands Capital LLC now owns 725,608 shares of the medical research company’s stock valued at $4,716,000 after purchasing an additional 225,558 shares during the last quarter. Wealthcare Advisory Partners LLC purchased a new position in shares of Cytosorbents in the 3rd quarter valued at approximately $365,000. PNC Financial Services Group Inc. grew its stake in shares of Cytosorbents by 145.2% in the 2nd quarter. PNC Financial Services Group Inc. now owns 38,000 shares of the medical research company’s stock valued at $163,000 after purchasing an additional 22,500 shares during the last quarter. Finally, Fortaleza Asset Management Inc. grew its stake in shares of Cytosorbents by 81.6% in the 3rd quarter. Fortaleza Asset Management Inc. now owns 23,375 shares of the medical research company’s stock valued at $145,000 after purchasing an additional 10,500 shares during the last quarter. Institutional investors own 9.47% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Cytosorbents (NASDAQ:CTSO) Given Buy Rating at HC Wainwright” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/01/cytosorbents-ctso-given-buy-rating-at-hc-wainwright.html.
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.